Customised drug therapy - How near is the goal?;Skreddersydd legemiddelbehandling - Hvor nær målet er vi?

Tidsskrift for den Norske Laegeforening

Volumn 126, Issue 18, 2006, Pages 2390-2396

  Spigset, Olav ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; DRUG METABOLIZING ENZYME; CYTOCHROME P450; DRUG;

ADVERSE DRUG REACTION; DRUG CHOICE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; INFORMATION RETRIEVAL; MEDLINE; PHARMACOGENETICS; REVIEW; RISK FACTOR; TREATMENT PLANNING; TREATMENT RESPONSE; DRUG DESIGN; GENETIC POLYMORPHISM; GENETICS; TREATMENT OUTCOME;

CARRIER PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 33749044646     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Spigset O. Fra konfeksjon til skreddersøm - fremtidige muligheter for individuelt tilpasset legemiddelbehandling. Tidsskr Nor Lægeforen 2000; 120: 73-6.
2. Spigset O. Cytokrom P-450-systemet. Tidsskr Nor Lægeforen 2001; 121: 3296-8.
3. Johansen PW, Bergan S, Rootwelt H et al. Individualisert farmakoterapi basert på cytokrom P-450 (CYP)-genotyping. Tidsskr Nor Lægeforen 2002; 29: 2781-3.
4. Rudberg I, Solberg DK, Refsum H. CYP-genotyping ved psykofarmakologisk behandling. Tidsskr Nor Lægeforen 2005; 125: 2953-5.
5. Roots I, Gerloff T, Meisel C et al. Pharmacogenetics-based new therapeutic concepts. Drug Metab Rev 2004; 36: 617-38.
6. Spigset O. Legemiddelinteraksjoner. I: Vilberg A, red. Norsk legemiddelhåndbok for helsepersonell. Oslo: Foreningen for utgivelse av Norsk legemiddelhåndbok, 2004: 1317-24.
7. Kirchheiner J, Brøsen K, Dahl ML et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-92.
8. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-73.
9. Güzey C, Spigset O. Genotyping as a tool to predict adverse drug reactions. Curr Top Med Chem 2004; 4: 1411-21.
10. Kirchheiner J, Fuhr U, Brockmöller J. Pharmacogenetics-based therapeutic recommendations - ready for clinical practice? Nat Rev Drug Discov 2005; 4: 639-47.
11. Loennechen T, Lysaa RA, Giverhaug T et al. Nye styringsverktøy for tiopuriner i leukemi- og transplantasjonsbehandling. Tidsskr Nor Lægeforen 2002; 122: 1107-10.
12. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr Top Med Chem 2004; 4: 1385-98.
13. Molden E. P-glykoprotein - en pumpe av betydning for legemiddelrespons. Tidsskr Nor Lægeforen 2004; 124: 2921-3.
14. Klepstad P, Dale O, Borchgrevink PC et al. Genetisk variasjon - viktig for klinisk virkning av opioider? Tidsskr Nor Lægeforen 2005; 125: 2655-8.
15. Tate SK, Depondt C, Sisodiya SM et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytion. Proc Natl Acad Sci U S A 2005; 102: 5507-12.
16. Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005; 46: 858-77.
17. Sparreboom A, Danesi R, Ando Y et al. Pharmacogenetics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003; 6: 71-86.
18. Lepper ER, Nooter K, Verweij J et al. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 2005; 6: 115-38.
19. Tirona RG, Kim RB. Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev 2002; 54: 1343-52.
20. Marzolini C, Tirona RG, Kim RB. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 2004; 5: 273-82.
21. Lappegård KT. Arvelig warfarinresistens. Tidsskr Nor Lægeforen 2000; 120: 3257-8.
22. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
23. Rozalski M, Boncler M, Luzak B et al. Genetic factors underlying differential blood platelet sensitivity to inhibitors. Pharmacol Rep 2005; 57: 1-13.
24. Pedley TA, Hirano M. Is refractory epilepsy due to genetically determined resistance to antiepileptic drugs? N Engl J Med 2003; 348: 1480-2.
25. Sagen JV, Ræder H, Hathout E et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2. Diabetes 2004; 53: 2713-8.
26. Bjørkhaug L, Johansson S, Ræder H et al. Molekylærgenetisk diagnostikk ved diabetes mellitus. Tidsskr Nor Lægeforen 2005; 125: 2968-72.
27. Hansen T, Echwald SM, Hansen K et al. Decreased tolbutamide-stimulated insulin secretion in healthy volunteers with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 1998; 47: 598-605.
28. 972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 2004; 27: 1394-8.
29. Mellen PB, Herrington DM. Pharmacogenomics of blood pressure response to antihypertensive treatment. J Hypertens 2005; 23: 1311-2.
30. Tantisira KG, Weiss ST. The pharmacogenetics of asthma: an update. Curr Opin Mol Ther 2005; 7: 209-17.
31. Güzey C, Spigset O. Genotyping of drug targets: a method to predict adverse drug reactions? Drug Saf 2002; 25: 553-60.
32. Berge KE, Haugaa KH, Anfinsen OG et al. Genteknologisk diagnostikk av lang QT-tid-syndrom. Tidsskr Nor Lægeforen 2005; 125: 2783-6.
33. Haugaa KH, Berge KE, Früh A et al. Kardiale kanalopatier - diagnostikk og behandling. Tidsskr Nor Lægeforen 2005; 125: 2778-81.
34. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 2004; 27: 145-72.
35. Bathen J, Spigset O. Lang QT-tid som bivirkning - risiko for fatale arytmier. Tidsskr Nor Lægeforen 2000; 120: 3432-4.
36. www.torsades.org (8.6.2006).
37. Perlis RH, Mischoulon D, Smoller JW et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003; 54: 879-83.
38. Murphy GM jr, Kremer C, Rodrigues HE et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830-5.
39. Murphy GM jr, Hollander SB, Rodrigues HE et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004: 61; 1163-9.
40. Hedenmalm K, Güzey C, Dahl ML et al. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26: 192-7.
41. Spigset O, Hedenmalm K, Dahl ML et al. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997; 96; 379-8.
42. Vandenbrouke JP, van der Meer FJM, Helmerhorst FM et al. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313: 1127-30.
43. Arranz MJ, Munro J, Birkett J et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355; 1615-6.
44. Sadée W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 2005; 14: R207-14.